1. Valeant Pharmaceuticals International gave $100,000 to a patient advocacy group after it told the drugmaker that patients were unable to afford its rare-disease drug Syprine. Valeant had raised the price of Syprine after acquiring it. (Bloomberg)
2. Omnicom Group said revenue for its specialty communications agencies, including the Omnicom Health Group, grew 3.3% organically in the first quarter of 2017.
3. Verily Life Sciences, Alphabet’s health-research outfit, began recruiting for a 10,000 volunteer study known as Baseline that aims to establish a foundation of healthy biometric data. Participants will receive a sleep sensor and a wristwatch meant to record their steps, sweat, and heart rate over a four-year period. (Bloomberg)
4. Theranos plans to return $4.6 million to residents in Arizona for any blood testing services rendered from 2013 to 2016. The startup struck a deal with Arizona’s attorney general under which the company will not operate a certain lab in Arizona for two years. (STAT)
5. The FDA has approved 13 new drugs this year, on pace to pass the 22 new drugs it approved in 2016. In 2015, the agency approved 45 drugs. (Endpts)
